Orange Book product · Brand (NDA)
NASONEX 24HR ALLERGY
MOMETASONE FUROATE
At a glance
Mar 17, 2022
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 17, 2022
4 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
MOMETASONE FUROATE
Strength
0.05MG/SPRAY
Dosage form
SPRAY, METERED
Route
NASAL
TE code
Not listed
Application
NDA 215712
Product number
001
Marketing status
OTC
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2019ASMANEX HFABrand (NDA)
NDA 205641 · ORGANON LLC
- 2017SINUVABrand (NDA)
NDA 209310 · INTERSECT ENT INC
- 2008ASMANEX TWISTHALERBrand (NDA)
NDA 021067 · ORGANON LLC
- 1997NASONEXBrand (NDA)
NDA 020762 · ORGANON LLC
- 1989ELOCONBrand (NDA)
NDA 019796 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019625 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019543 · ORGANON
- 2025MOMETASONE FUROATEGeneric (ANDA)
ANDA 211706 · NASPRESS
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217498 · AUROBINDO PHARMA
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217438 · APOTEX
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 215878 · AUROBINDO PHARMA
- 2023MOMETASONE FUROATEGeneric (ANDA)
ANDA 217460 · AMNEAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
